167 related articles for article (PubMed ID: 32941832)
1. Shifting paradigms in the systemic management of hepatocellular carcinoma.
Pinato DJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):883-885. PubMed ID: 32941832
[No Abstract] [Full Text] [Related]
2. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Minot-This MS; Edeline J
Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
[No Abstract] [Full Text] [Related]
3. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Hou Y; Wu B
Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
[No Abstract] [Full Text] [Related]
4. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li X; Song J; Zhu AX
Future Oncol; 2019 Jun; 15(16):1811-1822. PubMed ID: 30969136
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
Boland P; Wu J
Chin Clin Oncol; 2018 Oct; 7(5):50. PubMed ID: 30395717
[TBL] [Abstract][Full Text] [Related]
6. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
7. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
[TBL] [Abstract][Full Text] [Related]
8. Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma.
Varkaris A; Lewis DW; Nugent FW
Am J Gastroenterol; 2017 Dec; 112(12):1895-1896. PubMed ID: 29215617
[No Abstract] [Full Text] [Related]
9. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
Kudo M
World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
[TBL] [Abstract][Full Text] [Related]
10. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
Cheng AL
Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
[No Abstract] [Full Text] [Related]
11. Hepatocellular carcinoma in the era of immunotherapy.
Sim HW; Knox J
Curr Probl Cancer; 2018; 42(1):40-48. PubMed ID: 29150141
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for hepatocellular carcinoma.
Zongyi Y; Xiaowu L
Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
Mody K; Abou-Alfa GK
Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
Mazzolini GD; Malvicini M
Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of the advanced HCC: A second revolution by using immunotherapy].
Fartoux L; Rosmorduc O
Biol Aujourdhui; 2018; 212(3-4):85-87. PubMed ID: 30973137
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
O'Neil BH; Venook AP
Oncologist; 2007 Dec; 12(12):1425-32. PubMed ID: 18165619
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
Rammohan A; Reddy MS; Farouk M; Vargese J; Rela M
Hepatology; 2018 Mar; 67(3):1166-1168. PubMed ID: 29023959
[No Abstract] [Full Text] [Related]
18. The hepatocellular carcinoma market.
Dawkins J; Webster RM
Nat Rev Drug Discov; 2019 Jan; 18(1):13-14. PubMed ID: 30168534
[No Abstract] [Full Text] [Related]
19. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
20. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma.
Wang M; Wu M; Yang T
EBioMedicine; 2019 Feb; 40():11-12. PubMed ID: 30651221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
